Share this Article
Singapore Med J 2014; 55(4): 221-228; http://dx.doi.org/10.11622/smedj.2014056
Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit
Kunnoor NS, Devi P, Kamath DY, Anthony N, George J
Correspondence: Dr Nitin S Kunnoor, drnitinskunnoor@yahoo.in
ABSTRACT
INTRODUCTION This study aimed to examine age- and gender-related differences in the comorbidities, drug utilisation and adverse drug reaction (ADR) patterns of patients admitted to a coronary care unit (CCU).
METHODS The present study was a retrospective cohort study. Two trained physicians independently reviewed the case records of CCU patients over a period of one year (Jan–Dec 2008). The demographic, clinical, and drug prescription data of the patients were analysed according to age group (18–59 years vs ≥ 60 years) and gender.
RESULTS A total of 574 patients were admitted to the CCU during the study period. Of these 574 patients, 65.2% were male, and 48.4% were ≥ 60 years old. No significant gender-based differences were found for the prescription of cardiovascular and non-cardiovascular drugs, and ADR patterns (p > 0.05). Male patients aged ≥ 60 years were found to have a higher rate of polypharmacy than those aged 18–59 years (p = 0.001). The duration of hospital stay was longer in male than female patients (p = 0.008), and the duration of CCU stay was longer for male patients aged ≥ 60 years than males aged 18–59 years (p = 0.013). Compared to patients aged 18–59 years, a greater number of patients aged ≥ 60 years were prescribed cardiovascular (p = 0.006) and non-cardiovascular drugs (p = 0.015). Patients aged ≥ 60 years also had a higher rate of polypharmacy (p = 0.001) and ADRs (p = 0.013), and a longer duration of CCU stay (p = 0.013). Renal (p = 0.047) and cutaneous (p = 0.003) ADRs were found to be more common in patients aged ≥ 60 years.
CONCLUSION No major gender-related differences were observed in the prescription, drug utilisation and ADR patterns of our study cohort. Higher drug utilisation, ADR rates, and longer duration of CCU stay were noted in patients aged ≥ 60 years.
Keywords: adverse drug reactions, age, coronary care unit, drug utilisation, gender
Singapore Med J 2014; 55(4): 221-228; http://dx.doi.org/10.11622/smedj.2014056
REFERENCES
| 1. Surveillance of mortality and cardiovascular disease related morbidity in Industrial settings. WHO Country Office for India, Geneva, Switzerland [online]. Available at: www.georgeinstitute.org.au/global-health-landscape/global-health-resourc.... Accessed July 3, 2011. | ||||
| 2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e 25 -146. | ||||
| 3. Mendelson MA, Hendel RC. Myocardial infarction in women. Cardiology 1995; 86:272-85. http://dx.doi.org/10.1159/000176891 | ||||
| 4. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99:1165 -72. http://dx.doi.org/10.1161/01.CIR.99.9.1165 | ||||
| 5. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29:932-40. http://dx.doi.org/10.1093/eurheartj/ehn018 | ||||
| 6. Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009; 169:1762-6. http://dx.doi.org/10.1001/archinternmed.2009.318 | ||||
| 7. Vulic D, Lee BT, Dede J, Lopez VA, Wong ND. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey. Am J Cardiovasc Drugs 2010; 10:109-14. http://dx.doi.org/10.2165/11535240-000000000-00000 | ||||
| 8. de Ruijter W, de Waal MW, Gussekloo J, Assendelft WJ, Blom JW. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract 2010; 60:47-9. http://dx.doi.org/10.3399/bjgp10X482103 | ||||
| 9. Gnavi R, Migliardi A, Demaria M, et al. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 2007; 17:492-6. http://dx.doi.org/10.1093/eurpub/ckm005 | ||||
| 10. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in highrisk elderly patients: the treatment-risk paradox. JAMA 2004; 291:1864-70. http://dx.doi.org/10.1001/jama.291.15.1864 | ||||
| 11. Driscoll A, Beauchamp A, Lyubomirsky G, et al. Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in women. Intern Med J 2011; 41:730-6. http://dx.doi.org/10.1111/j.1445-5994.2011.02534.x | ||||
| 12. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277:307-11. http://dx.doi.org/10.1001/jama.1997.03540280045032 | ||||
| 13. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2:349-51. http://dx.doi.org/10.2165/00128071-200102060-00001 | ||||
| 14. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114:956-66. http://dx.doi.org/10.7326/0003-4819-114-11-956 | ||||
| 15. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007; 2:79-87. http://dx.doi.org/10.2174/157488607779315507 | ||||
| 16. Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf 2010; 19:889-94. http://dx.doi.org/10.1002/pds.1916 | ||||
| 17. Devi P, Kamath DY, Anthony N, Santosh S, Dias B. Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital. Eur J Clin Pharmacol 2012; 68:427-33. http://dx.doi.org/10.1007/s00228-011-1138-9 | ||||
| 18. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. Oslo, 2010. 1-8-2012 [online]. Available at: www.whocc.no/filearchive/publications/2011guidelines.pdf. Accessed August 1, 2012. | ||||
| 19. World Health Organization. International Classification of Diseases Version 10. 1-8-2012 [online]. Available at: www.apps.who.int/classifications/icd10/browse/2010/en. Accessed August 1, 2012. | ||||
| 20. World Health Organization. International drug monitoring- the role of national centres. Technical Report No.498, World Health Organisation, Geneva [online]. Available at: www.who-umc.org/graphics/24756.pdf. Accessed August 1, 2012. | ||||
| 21. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005; 45:832-7. http://dx.doi.org/10.1016/j.jacc.2004.11.055 | ||||
| 22. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275:1104-12. http://dx.doi.org/10.1001/jama.1996.03530380046030 | ||||
| 23. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009; 54:1561-75. http://dx.doi.org/10.1016/j.jacc.2009.04.098 | ||||
| 24. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-40. http://dx.doi.org/10.1056/NEJMra061889 | ||||
| 25. Banerjee S, Kumar V, Ramachandran P, Kamath A. Does The Pharmacological Management Of Unstable Angina Vary With Age And Gender – A Descriptive Study. J Clin Diag Res 2010; 4:3150-57. | ||||
| 26. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag 2005; 1:217-25. | ||||
| 27. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 suppl 1):S1-266. http://dx.doi.org/10.1016/S0272-6386(02)70132-7 | ||||
| 28. National Institute for Health and Clinical Excellence, United Kingdom. Chronic Heart Failure: Management of chronic heart failure in adults in primary and secondary care (Issued: August 2010). Available at: http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf. Accessed March 24, 2014. | ||||
| 29. National Institute for Health and Care Excellence, United Kingdom. Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care (Issued: September 2008). Available at: http://www.nice.org.uk/nicemedia/live/12069/42117/42117.pdf. Accessed March 24, 2014. | ||||
| 30. Xavier D, Pais P, Devereaux PJ, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008; 371:1435-42. http://dx.doi.org/10.1016/S0140-6736(08)60623-6 | ||||
| 31. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail 1999; 5:184-5. | ||||
| 32. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-8. http://dx.doi.org/10.1056/NEJM200105313442201 | ||||
| 33. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incor porated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391-e479. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192065 | ||||
| 34. Marandi T, Baburin A, Ainla T. Use of evidence-based pharmacotherapy after myocardial infarction in Estonia. BMC Public Health 2010; 10:358. http://dx.doi.org/10.1186/1471-2458-10-358 | ||||
| 35. Ghosh A, Das AK, Pramanik S, Saha UK. Drug utilization study in patients of acute coronary syndrome on follow-up visits at a tertiary care centre In Kolkata. Asian J Pharm Life Sci 2013; 2:155-65. | ||||
| 36. Verkerk AO, Wilders R, Veldkamp MW, et al. Gender disparities in cardiac cellular electrophysiology and arrhythmia susceptibility in human failing ventricular myocytes. Int Heart J 2005; 46:1105-18. http://dx.doi.org/10.1536/ihj.46.1105 | ||||
| 37. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891. http://dx.doi.org/10.1136/bmj.d4891 | ||||
| 38. Zaitune MP, Barros MB, Cesar CL, Carandina L, Goldbaum M. [Arterial hypertension in the elderly: prevalence, associated factors, and control practices in Campinas, Sao Paulo, Brazil]. Cad Saude Publica 2006; 22:285-94. Portuguese. http://dx.doi.org/10.1590/S0102-311X2006000200006 | ||||
| 39. Suominen-Taipale AL, Martelin T, Koskinen S, Holmen J, Johnsen R. Gender differences in health care use among the elderly population in areas of Norway and Finland. A cross-sectional analysis based on the HUNT study and the FINRISK Senior Survey. BMC Health Serv Res 2006; 6:110 http://dx.doi.org/10.1186/1472-6963-6-110 | ||||
| 40. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007; 2:79-87. http://dx.doi.org/10.2174/157488607779315507 | ||||
| 41. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980; 18:362-6. | ||||
| 42. Karimzadeh I, Namazi S, Shalviri G, Gholami K. Cardiovascular drug adverse reactions in hospitalized patients in cardiac care unit. African J Pharm Pharmacol 2011; 5:493-9. http://dx.doi.org/10.5897/AJPP10.413 | ||||
| 43. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004; 57:121-6. http://dx.doi.org/10.1046/j.1365-2125.2003.01875.x | ||||